There is provided compounds of formula (I), or pharmaceutically-acceptable salts thereof, wherein X, Y, Z, R.sup.1 and R.sup.2 have meanings provided in the description, which compounds are useful in the treatment of cancers. ##STR00001##

There is provided compounds of formula (I), or pharmaceutically-acceptable salts thereof, wherein X, Y, Z, R.sup.1 and R.sup.2 have meanings provided in the description, which compounds are useful in the treatment of cancers. ##STR00001##

Methods of treating a subject suffering from COVID-19 are provided. Aspects of the methods including administering to the subject an effective amount of an inhibitor of CCR5/CCL5 interaction, such as a CCR5 antagonist. Also provided are methods of assessing severity of a disease involving hypercytokinemia, such as COVID-19, by determining the level of CCL5/RANTES in a subject, as well as compositions for use in such methods.

The invention provides compounds of Formula XXIII: ##STR00001##
wherein R.sub.1 is hydrogen, alkyl, acyl, or silyl, R.sub.2 is hydrogen, alkyl, benzyl, acyl, or ester, and R.sub.3 is hydrogen, alkyl, an aromatic group, azacyclic, carbocycle, aryl, cycloalkyl, heterocycloalkyl, heterocycle, heteroaryl, heteroalkyl, acyl, or ester, as well as derivatives and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

The invention provides compounds of Formula XXIII: ##STR00001##
wherein R.sub.1 is hydrogen, alkyl, acyl, or silyl, R.sub.2 is hydrogen, alkyl, benzyl, acyl, or ester, and R.sub.3 is hydrogen, alkyl, an aromatic group, azacyclic, carbocycle, aryl, cycloalkyl, heterocycloalkyl, heterocycle, heteroaryl, heteroalkyl, acyl, or ester, as well as derivatives and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

A compound or a salt thereof represented by Formula (I). An LSD1 inhibitor containing the compound or a salt thereof as an active ingredient. A pharmaceutical composition containing the compound or salt thereof. An antitumor agent containing the compound or a salt thereof as an active ingredient.

A compound or a salt thereof represented by Formula (I). An LSD1 inhibitor containing the compound or a salt thereof as an active ingredient. A pharmaceutical composition containing the compound or salt thereof. An antitumor agent containing the compound or a salt thereof as an active ingredient.

There is provided compounds of formula (I), or pharmaceutically-acceptable salts thereof, wherein X, Y, Z, R.sup.1 and R.sup.2 have meanings provided in the description, which compounds are useful in the treatment of cancers.

##STR00001##

There is provided compounds of formula (I), or pharmaceutically-acceptable salts thereof, wherein X, Y, Z, R.sup.1 and R.sup.2 have meanings provided in the description, which compounds are useful in the treatment of cancers.

##STR00001##

The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.